[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Clinical Guidelines Synopsis
February 4, 2019

Management of Blood Cholesterol

Author Affiliations
  • 1Department of Medicine, University of Chicago, Chicago, Illinois
JAMA. 2019;321(8):800-801. doi:10.1001/jama.2019.0015

Pharmacologically lowering low-density lipoprotein cholesterol (LDL-C) consistently reduces ASCVD events (myocardial infarction, stroke, and cardiovascular death), and the principle that lower LDL-C is better was reaffirmed by trials that added ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to statin therapy.1,2 The 2013 guideline removed specific LDL-C treatment targets, but high-quality trials since offered the opportunity to reintroduce such goals based on risk gradations.